PIPERACILLIN TAZOBACTAM COMPARED WITH CO-AMOXICLAV, AMPICILLIN PLUS SULBACTAM AND TIMENTIN AGAINST BETA-LACTAMASE-PRODUCING CLINICAL ISOLATES OF ESCHERICHIA-COLI, KLEBSIELLA-PNEUMONIAE AND KLEBSIELLA-OXYTOCA

被引:3
作者
TRAUB, WH
LEONHARD, B
机构
[1] Inst. Med. Hygiene und Mikrobiologie, Universitat des Saarlandes
关键词
AGAR DILUTION METHOD; AGAR DISK DIFFUSION TEST; AMOXICILLIN; AMPICILLIN; BAUER-KIRBY METHOD; CLAVULANIC ACID; CO-AMOXICLAV; ENTEROBACTERIACEAE; BETA-LACTAMASES; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN; TIMENTIN;
D O I
10.1159/000239366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A total of 266 enterobacterial isolates (Escherichia coli = 190, Klebsiella pneumoniae = 49, K. oxytoca = 27) were tested for susceptibility (Bauer-Kirby agar disk diffusion test and agar dilution procedure) to ampicillin, ampicillin in 10 mu g/ml of sulbactam, amoxicillin in 4 mu g/ml of clavulanic acid, piperacillin, piperacillin plus tazobactam (8:1 ratio), ticarcillin and timentin (ticarcillin in 4 mu g/ml of clavulanic acid). Discrepant results between the two methods of susceptibility testing were categorized as follows: category I = very major [minimal inhibitory concentration (MIC) = resistant, disk diffusion = susceptible] category II = major (MIC = susceptible, disk diffusion = resistant), category III = minor (MIC = intermediate susceptibility, disk diffusion = susceptible) category IV = slight (MIC = resistant, disk diffusion = intermediate), category V = minimal (MIC = susceptible, disk diffusion = intermediate) and category VI = negligible (MIC = intermediate, disk diffusion = resistant). The antibiotics, or combinations with beta-lactamase inhibitors, yielded the following discrepant results: ampicillin (II = 2, V = 1 and VI = 3), co-amoxiclav (I = 5, III = 25, IV = 1 and V = 3), ampicillin plus sulbactam (I = 5, II = 3, III = 1, V = 19 and VI = 1), piperacillin (II = 15, III = 1, V = 15 and VI = 85), piperacillin plus tazobactam (III = 16, IV = 2, V = 1 and VI = 5) and timentin (I = 2, III = 48 and IV = 1). It was proposed that the currently valid criterion (greater than or equal to 18 mm) of inhibition zones indicating susceptibility of Enterobacteriaceae to co-amoxiclav be modified to greater than or equal to 20 mm. Furthermore, a change in the inhibition zone criterion indicating intermediate susceptibility of enterobacterial isolates to piperacillin from the current 18-20 to 14-20 mm in diameter would solve the majority of encountered category VI discrepancies. It was decided to exclude ampicillin/sulbactam (10/10 mu g) and timentin (75/10 mu g) disks from the test battery for Enterobacteriaceae, but rather test isolates for susceptibility to co-amoxiclav and/or piperacillin plus tazobactam.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 42 条
[1]  
[Anonymous], 1993, M7A3 NAT COMM CLIN L
[2]   AMPICILLIN-SULBACTAM SUSCEPTIBILITY TESTING CRITERIA [J].
BARRY, A ;
PFALLER, M ;
FUCHS, P ;
GERLACH, E ;
HARDY, D ;
MCLAUGHLIN, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (06) :469-472
[3]  
BARRY AL, 1978, AM J CLIN PATHOL, V70, P909
[4]   TICARCILLIN AND TICARCILLIN-CLAVULANIC ACID SUSCEPTIBILITY TESTS - ERROR RATES FOR DISK TESTS WITH CONSECUTIVELY ISOLATED MEMBERS OF THE FAMILY ENTEROBACTERIACEAE [J].
BARRY, AL ;
FUCHS, PC ;
GERLACH, EH ;
HARDY, DJ ;
MCLAUGHLIN, JC ;
PFALLER, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :137-143
[5]  
BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
[6]  
BOURGAULT AM, 1979, J CLIN MICROBIOL, V9, P654
[7]   USE OF A PREDICTOR PANEL TO EVALUATE SUSCEPTIBILITY TEST METHODS PROPOSED FOR PIPERACILLIN-TAZOBACTAM [J].
BRADFORD, PA ;
SANDERS, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (12) :2578-2583
[8]   CHARACTERIZATION OF BETA-LACTAMASES [J].
BUSH, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :259-263
[10]   KINETIC INTERACTIONS OF TAZOBACTAM WITH BETA-LACTAMASES FROM ALL MAJOR STRUCTURAL CLASSES [J].
BUSH, K ;
MACALINTAL, C ;
RASMUSSEN, BA ;
LEE, VJ ;
YANG, YJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :851-858